Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 21, 2019. The document serves as a transaction notification regarding a specific share transfer involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of a specific transaction and does not contain financial performance data.
Material Changes
The filing details a single transaction involving the transfer of 121,802 Ordinary Shares (ISIN: GB0009252882) between accounts for nil consideration (£0.00). The transaction occurred on February 20, 2019, and involved Mr. S Dingemans, the Chief Financial Officer.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosed transaction.
Investor Verification Points
- Verify the nature of the share transfer (nil consideration) for CFO S Dingemans.
- Confirm the transaction date of February 20, 2019.
- Note that this filing contains no financial performance metrics or strategic updates.